nCounter® Myeloid Innate Immunity Panel
Helping Your Research
The nCounter® Myeloid Innate Immunity Panel provides comprehensive coverage of myeloid-derived cells in a targeted gene expression assay. These panels can be used with multiple sample types like peripheral blood mononuclear cells (PBMCs) or formalin-fixed paraffin-embedded (FFPE) tissue sections and provide results in less than 24 hours with minimal hands-on time and data analysis.
The Myeloid Innate Immunity Panel is designed to encompass all aspects of the innate immune response of myeloid-derived cells and can be used for basic and translational research in immuno-oncology, autoimmunity, and infectious disease. The panel is curated to include the most current and relevant genes and is available in both human and mouse versions. Use the Myeloid Innate Immunity Panel to study:
- Mechanisms of immune evasion
- Damage response, wound healing & tissue repair
- Immune regulation
- Disease pathogenesis
- Treatment response vs. non-response
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
Publications
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.
Contact Us
Have questions or simply want to learn more?
Contact our helpful experts and we’ll be in touch soon.